单次唾液采样预测利奈唑胺剂量:耐多药结核的血浆与唾液群体药代动力学模型
本研究在17例接受利奈唑胺治疗≥7天的耐多药结核成人中,采集102对血浆与唾液样本,建立唾液-血浆群体药代动力学模型,并评估有限采样策略预测血浆AUC0-24的性能。结果显示,单次唾液样本(给药前或给药后2小时)即可准确预测血浆AUC0-24(中位偏差<5%),支持唾液TDM作为血浆监测的实用替代方案。
要点
- 单次唾液样本(给药前或给药后2小时)可准确预测利奈唑胺血浆AUC0-24,中位偏差<5%。
- 三样本唾液策略(给药前、2小时、5小时)预测血浆AUC0-24的中位偏差<5%。
- 体重影响表观分布容积,指数为1.1(95%CI 1.01-1.18)。
核心结论
- 验证的唾液-血浆群体药代动力学模型可利用有限唾液样本可靠估计利奈唑胺血浆AUC0-24。
- 单次唾液样本(给药前或给药后2小时)即可准确预测血浆AUC0-24,中位偏差<5%。
研究设计与样本
- 研究纳入17例接受利奈唑胺治疗≥7天的耐多药结核成人,采集102对血浆与唾液样本。
- 在给药前、给药后2小时和5小时采集样本,使用NONMEM建立唾液-血浆群体药代动力学模型并进行协变量分析。
- 采用贝叶斯估计和蒙特卡洛模拟评估唾液有限采样策略预测血浆AUC0-24的性能,以±20%偏差为可接受标准。
主要发现
- 含唾液假想效应室的一室血浆模型(一级吸收和消除)最佳描述数据。
- 体重影响表观分布容积,指数为1.1(95%CI 1.01-1.18)。
- 三样本唾液策略(给药前、2小时、5小时)预测血浆AUC0-24的中位偏差<5%。
- 单次唾液样本(给药前或给药后2小时)预测血浆AUC0-24的中位偏差<5%。
临床怎么用
- 可采用单次唾液样本(给药前或给药后2小时)替代血浆采样进行利奈唑胺TDM,预测血浆AUC0-24。
- 唾液TDM可作为耐多药结核患者利奈唑胺监测的实用替代方案,降低侵入性采样负担。
局限性
- 研究样本量较小(17例患者,102对样本),需更大规模验证。
- 模型基于接受利奈唑胺治疗≥7天的成人耐多药结核患者,其他人群适用性未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Therapeutic drug monitoring (TDM) of linezolid for treating multidrug-resistant tuberculosis (MDR-TB) is recommended but is hindered by the invasive and logistical challenges of plasma sampling. Saliva is a promising alternative, but a saliva pharmacokinetic model to inform dosing is lacking. This study aimed to develop a saliva-based population pharmacokinetic (popPK) model and evaluate limited sampling strategies for linezolid in MDR-TB. METHODS: Plasma and saliva samples were collected at pre-dose, 2-, and 5-h post-dose from adults treated with linezolid for ≥ 7 days. A saliva-plasma popPK model was developed in NONMEM with covariate analysis. Bayesian estimation and Monte Carlo simulations were used to evaluate the predictive performance of saliva limited sampling strategies for predicting plasma AUC0-24. A ±20% bias versus reference was considered acceptable. RESULTS: One-compartment plasma model incorporating a saliva hypothetical effect compartment with first-order absorption and elimination best described the data (102 paired saliva-plasma samples, 17 patients). Body weight influenced volume of distribution with an exponent of 1.1 (95% CI 1.01-1.18). The three-sample (pre-dose, 2-, and 5-h) saliva strategy adequately predicted plasma AUC0-24 with < 5% median bias. A single saliva sample at pre-dose or 2 h post-dose provided accurate plasma AUC0-24 predictions (< 5% median bias). CONCLUSIONS: The validated model enables reliable estimation of plasma AUC0-24 using limited saliva samples. A single saliva sample (pre-dose or 2 h post-dose) can accurately predict plasma AUC0-24, supporting saliva-based TDM as a practical alternative to plasma-based monitoring of linezolid in MDR-TB.
引用
- Nguyen TA, Nguyen TP, Nguyen AT, et al. Single Saliva Sample Linezolid Dosing for Multidrug-Resistant Tuberculosis: A Population Pharmacokinetic Modelling of Plasma and Saliva. Clin Pharmacokinet. 2026. PMID: 41845154. doi:10.1007/s40262-026-01626-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。